CC
KALV

Commodore Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Commodore Capital’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-312,553
Closed -$2.81M – 32
2023
Q2 		$2.81M Hold
312,553
– – 0.32% 24
2023
Q1 		$2.46M Hold
312,553
– – 0.37% 29
2022
Q4 		$2.11M Hold
312,553
– – 0.32% 34
2022
Q3 		$4.54M Hold
312,553
– – 0.73% 24
2022
Q2 		$3.08M Hold
312,553
– – 0.65% 21
2022
Q1 		$4.61M Hold
312,553
– – 1.03% 21
2021
Q4 		$4.13M Hold
312,553
– – 0.96% 18
2021
Q3 		$5.45M Buy
312,553
+85,882
+38% +$1.74M 1.44% 22
2021
Q2 		$5.43M Buy
226,671
+12,204
+6% +$319K 1.89% 22
2021
Q1 		$5.51M Buy
+214,467
New +$5.64M 2.19% 20

Other funds holding KALV

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Commodore Capital's KALV Position: Q3 2023 in Review

Commodore Capital sold out of KalVista Pharmaceuticals (KALV) in Q3 2023, closing a stake of 312,553 shares — an estimated $2.81M sold.

Commodore Capital first reported a position in KALV in Q1 2021 and held it in 10 quarters. The position peaked at $5.51M in Q1 2021. 101 funds tracked by Wall St. Rank hold KALV as of Q3 2023.

  • Commodore Capital reported no remaining KalVista Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Commodore Capital sold 312,553 KalVista Pharmaceuticals shares in Q3 2023, an estimated $2.81M.
  • Commodore Capital first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 10 quarters.
  • Commodore Capital's KalVista Pharmaceuticals position peaked at $5.51M in Q1 2021.
  • 101 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2023.

Based on Commodore Capital's 13F filing for Q3 2023, filed 14 Nov 2023.